Discovery of Two Novel Immunoepitopes and Development of a Peptide-based Sarcoidosis Immunoassay

• Published in: American journal of respiratory and critical care medicine Vol. 210; no. 7; pp. 908 - 918
• Main Authors: Peng, Changya, Talreja, Jaya, Steinbauer, Brennen, Shinki, Kazuhiko, Koth, Laura L., Samavati, Lobelia
• Format: Journal Article
• Language: English
• Published: United States American Thoracic Society 01.10.2024
• Subjects: Adult; Aged; Animals; Bioassays; Biomarkers; Enzyme-Linked Immunosorbent Assay - methods; Epitopes - immunology; Female; Humans; Immunoassay - methods; Immunoglobulin G - blood; Immunoglobulin G - immunology; Lung Neoplasms - diagnosis; Lung Neoplasms - immunology; Male; Medical diagnosis; Medical research; Middle Aged; Rabbits; Sarcoidosis; Sarcoidosis - blood; Sarcoidosis - diagnosis; Sarcoidosis - immunology; Sensitivity and Specificity; T7 phage display; sarcoidosis; cofilin; antigen; chain A
• ISSN: 1073-449X; 1535-4970; 1535-4970
• DOI: 10.1164/rccm.202306-1054OC

Sarcoidosis is a systemic granulomatous disorder associated with hypergammaglobulinemia and the presence of autoantibodies. The specific antigens initiating granulomatous inflammation in sarcoidosis are unknown, and there is no specific test available to diagnose sarcoidosis. To discover novel sarcoidosis antigens, we developed a high-throughput T7 phage display library derived from the sarcoidosis cDNA and identified numerous clones differentiating sarcoidosis from other respiratory diseases. After clone sequencing and a homology search, we identified two epitopes (cofilin μ and chain A) that specifically bind to serum IgGs of patients with sarcoidosis. To develop and validate an epitope-specific IgG-based immunoassay specific for sarcoidosis. We chemically synthesized both immunoepitopes (cofilin μ and chain A) and generated rabbit polyclonal antibodies against both neoantigens. After extensive standardization, we developed a direct peptide ELISA and measured epitope-specific IgG in the sera of 386 subjects, including healthy control subjects (  = 100), three sarcoidosis cohorts (  = 186), pulmonary tuberculosis (  = 70), and lung cancer (  = 30). To develop a model to classify sarcoidosis distinctly from other groups, data were analyzed using fivefold cross-validation when adjusting for confounders. The cofilin μ IgG model yielded a mean sensitivity, specificity, and positive and negative predictive value of 0.97, 0.9, 0.9, and 0.96, respectively. Those same measures for chain A IgG antibody were 0.9, 0.83, 0.84, and 0.9, respectively. Combining both biomarkers improved the area under the curve, sensitivity, specificity, and positive and negative predictive value. These results provide a novel immunoassay for sarcoidosis. The discovery of two neoantigens facilitates the development of biospecific drug discovery and the sarcoidosis-specific model.